Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04272216 · ClinicalTrials.gov registry record
An Observational Study of Radial Access Embolization Procedures Using HydroPearl Microspheres
A clinical trial of Benign Prostatic Hyperplasia and Uterine Fibroid, sponsored by Terumo Medical Corporation.
- Completed
- Registry status
- 99
- Enrollment target
- 6
- Study locations
NCT04272216: Completed study of Benign Prostatic Hyperplasia and Uterine Fibroid, sponsored by Terumo Medical Corporation.
NCT04272216 is a study of Benign Prostatic Hyperplasia and Uterine Fibroid that has completed, run by Terumo Medical Corporation. The registered enrollment target is 99 participants, below the 549-participant average among 29 other Benign Prostatic Hyperplasia trials with a reported enrollment target (82% lower). The trial reports 6 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04272216, a study of Benign Prostatic Hyperplasia and Uterine Fibroid, has completed, sponsored by Terumo Medical Corporation.
- COMPLETED
- Registry status
- 99 participants
- Enrollment target
- 6
- Study locations
Study Summary
This registry study is designed to collect data on the procedural success and complication rates in real-world patients undergoing HydroPearl embolization procedures via radial access.
Primary Outcome
Defined as completing the planned procedure without femoral access bailout
Conditions Studied
Interventions
- DEVICE Treatment with HydroPearl via radial access
Study Locations (6)
California
- University of California - Los Angeles - Los Angeles
Illinois
- Rush University Medical Center - Chicago
Missouri
- SLU Department of Radiology - St Louis
New York
- Mount Sinai - New York
North Carolina
- UNC - Chapel Hill
South Carolina
- Medical University of South Carolina - Charleston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 99 participants |
| Start Date | 2020-02-06 |
| Est. Completion | 2023-03-11 |
What the finished NCT04272216 record still lists
NCT04272216 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 99 participants, a relatively small participant target, below the 549-participant average among 29 other Benign Prostatic Hyperplasia trials with a reported enrollment target (82% lower).
The record links to 4 conditions, with Benign Prostatic Hyperplasia appearing as the primary indexed condition, and to 1 intervention - of which Treatment with HydroPearl via radial access is the first listed.
NCT04272216 lists 6 locations in 6 states (California, Illinois, Missouri).
Frequently Asked Questions
What is clinical trial NCT04272216 about?
NCT04272216 is a clinical study titled "An Observational Study of Radial Access Embolization Procedures Using HydroPearl Microspheres". This registry study is designed to collect data on the procedural success and complication rates in real-world patients undergoing HydroPearl embolization procedures via radial access.
What is the current status of trial NCT04272216?
This trial is currently completed. The enrollment target is 99 participants. The study started on 2020-02-06. Estimated completion is 2023-03-11.
What conditions does trial NCT04272216 study?
This clinical trial studies the following conditions: Benign Prostatic Hyperplasia, Uterine Fibroid, Arteriovenous Malformations, Hypervascular Tumors.
What interventions are being tested in trial NCT04272216?
The interventions under investigation include: Treatment with HydroPearl via radial access (DEVICE).
Who is sponsoring clinical trial NCT04272216?
This trial is sponsored by Terumo Medical Corporation, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04272216 being conducted?
This trial has 6 study locations across California, Illinois, Missouri, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Benign Prostatic Hyperplasia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04272216's enrollment target sits among peer trials
99 21st of 29 higher than 9 of 29 other Benign Prostatic Hyperplasia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Benign Prostatic Hyperplasia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Customized TULSA-PRO Ablation Registry
RECRUITING
-
OPtilume™ BPH Catheter SystEm for Treatment of Men eXperiencing Symptomatic BPH
RECRUITING
-
Ambulatory Long Length URodynamics Evaluation
RECRUITING · NA
-
Safety and Effectiveness of the Optilume® BPH Catheter System in a Post-Market Study
RECRUITING · NA
-
Sacral Neuromodulation for Male Overactive Bladder (MOAB)
RECRUITING · NA
-
A Clinical Study to Evaluate the Safety and Efficacy of the FloStent in Men With Benign Prostatic Hyperplasia Symptoms
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03965234 · 99 participants · Phase 1
Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases
- NCT04022616 · 99 participants
Myeloid-Derived Suppressor Cell Function in Breast Cancer Patients
- NCT04042844 · 99 participants · Phase 2
A Single Dose of BRTX 100 for Patients With Chronic Lumbar Disc Disease (cLDD)
- NCT04143724 · 99 participants · Phase 2
Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI